The role of mast cells after solid organ transplantation

Transplantation

Volumn 85, Issue 10, 2008, Pages 1365-1371

  Jahanyar, Jama ^a   Koerner, Michael M ^a,b   Loebe, Matthias ^a,b   Youker, Keith A ^b   Torre Amione, Guillermo ^b   Noon, George P ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Allograft tolerance; Fibrosis; Mast cells; Organ rejection

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CALCINEURIN INHIBITOR; CARBOXYPEPTIDASE A; CATHEPSIN G; CHYMASE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HISTAMINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; NERVE GROWTH FACTOR; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN; SEROTONIN; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CHRONIC GRAFT REJECTION; CYTOKINE RELEASE; FIBROSIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MAST CELL; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; ACUTE DISEASE; ALLOTRANSPLANTATION; CHRONIC DISEASE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; PHYSIOLOGY;

ACUTE DISEASE; CHRONIC DISEASE; GRAFT REJECTION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAST CELLS; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 48649107788     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816fc0a3     Document Type: Review

References (69)

1. Leslie M. Mast cells show their might. Science 2007; 317: 614.
2. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996; 381: 75.
3. Malaviya R, Ikeda T, Ross E, et al. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996; 381: 77.
4. Marx J. Immunology. Mast cells defang snake and bee venom. Science 2006; 313: 427.
5. Metz M, Piliponsky AM, Chen CC, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 2006; 313: 526.
6. Burns AR, Bowden RA, Abe Y, et al. P-selectin mediates neutrophil adhesion to endothelial cell borders. J Leukoc Biol 1999; 65: 299.
7. Huang C, De Sanctis GT, O'Brien PJ, et al. Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung. J Biol Chem 2001; 276: 26276.
8. Huang C, Friend DS, Qiu WT, et al. Induction of a selective and persistent extravasation of neutrophils into the peritoneal cavity by tryptase mouse mast cell protease 6. J Immunol 1998; 160: 1910.
9. Malaviya R, Ross EA, MacGregor JI, et al. Mast cell phagocytosis of FimH-expressing enterobacteria. J Immunol 1994; 152: 1907.
10. Marone G, Gentile M, Petraroli A, et al. Histamine-induced activation of human lung macrophages. Int Arch Allergy Immunol 2001; 124: 249.
11. McLachlan JB, Hart JP, Pizzo SV, et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol 2003; 4: 1199.
12. Suto H, Nakae S, Kakurai M, et al. Mast cell-associated TNF promotes dendritic cell migration. J Immunol 2006; 176: 4102.
13. Frandji P, Oskeritzian C, Cacaraci F, et al. Antigen-dependent stimulation by bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma. J Immunol 1993; 151: 6318.
14. Malaviya R, Twesten NJ, Ross EA, et al. Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J Immunol 1996; 156: 1490.
15. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442: 997.
16. Kirshenbaum AS, Goff JP, Semere T, et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(-), c-kit(-), and expresses aminopeptidase N (CD13). Blood 1999; 94: 2333.
17. Galli SJ. New concepts about the mast cell.NEngl J Med 1993; 328: 257.
18. Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol 1989; 7: 59.
19. Schwartz LB. Analysis of MC(T) and MC(TC) mast cells in tissue. Methods Mol Biol 2006; 315: 53.
20. Jahanyar J, Youker KA, Loebe M, et al. Mast cell-derived cathepsin G: A possible role in the adverse remodeling of the failing human heart. J Surg Res 2007; 140: 199.
21. Huang C, Sali A, Stevens RL. Regulation and function of mast cell proteases in inflammation. J Clin Immunol 1998; 18: 169.
22. Pilewski JM, Panettieri RA Jr, Kaiser LR, et al. Expression of endothelial cell adhesion molecules in human bronchial xenografts. Am J Respir Crit Care Med 1994; 150: 795.
23. Galli SJ. Mast cells and basophils. Curr Opin Hematol 2000; 7: 32.
24. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990; 346: 274.
25. Grimbaldeston MA, Nakae S, Kalesnikoff J, et al. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007; 8: 1095.
26. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as "tunable" effector and immunoregulatory cells: Recent advances. Annu Rev Immunol 2005; 23: 749.
27. Subba Rao PV, Friedman MM, Atkins FM, et al. Phagocytosis of mast cell granules by cultured fibroblasts. J Immunol 1983; 130: 341.
28. Skrabal CA, Thompson LO, Southard RE, et al. Interaction between isolated human myocardial mast cells and cultured fibroblasts. J Surg Res 2004; 118: 66.
29. Colvin RB, Dvorak HF. Letter: Basophils and mast cells in renal allograft rejection. Lancet 1974; 1: 212.
30. Greenstein SM, Katz JP, Hakki A, et al. Mast cells in ureters from rejected allografts. Transplant Proc 1989; 21: 286.
31. Li QY, Raza-Ahmad A, MacAulay MA, et al. The relationship of mast cells and their secreted products to the volume of fibrosis in posttransplant hearts. Transplantation 1992; 53: 1047.
32. Lajoie G, Nadasdy T, Laszik Z, et al. Mast cells in acute cellular rejection of human renal allografts. Mod Pathol 1996; 9: 1118.
33. Yousem SA. The potential role of mast cells in lung allograft rejection. Hum Pathol 1997; 28: 179.
34. El-Refaie AM, Burt AD. Mast cells and c-Kit expression in liver allograft rejection. Histopathology 2005; 47: 375.
35. Minami M, Nakahara K, Matsumura A, et al. Histamine release from pulmonary mast cells after lung transplantation in rats. J Heart Lung Transplant 1995; 14: 505.
36. Koskinen PK, Kovanen PT, Lindstedt KA, et al. Mast cells in acute and chronic rejection of rat cardiac allografts-a major source of basic fibroblast growth factor. Transplantation 2001; 71: 1741.
37. O'Keeffe C, Baird AW, Nolan N, et al. Mast cell hyperplasia in chronic rejection after liver transplantation. Liver Transpl 2002; 8: 50.
38. Zelenika D, Adams E, Humm S, et al. The role of CD4- T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev 2001; 182: 164.
39. Waldmann H. Immunology: Protection and privilege. Nature 2006; 442: 987.
40. Boerma M, Fiser WP, Hoyt G, et al. Influence of mast cells on outcome after heterotopic cardiac transplantation in rats. Transpl Int 2007; 20: 256.
41. Walgenbach KJ, Heeckt PF, Stanson JD, et al. Increased presence of mast cells and interleukin-4 during chronic rejection of rat intestinal allografts. Transplant Proc 1996; 28: 2454.
42. Pardo J, Diaz L, Errasti P, et al. Mast cells in chronic rejection of human renal allografts. Virchows Arch 2000; 437: 167.
43. Roberts IS, Brenchley PE. Mast cells: The forgotten cells of renal fibrosis. J Clin Pathol 2000; 53: 858.
44. Basadonna GP, Matas AJ, Gillingham KJ, et al. Relationship between early vs late acute rejection and onset of chronic rejection in kidney transplantation. Transplant Proc 1993; 25: 910.
45. Miller GG, Davis SF, Atkinson JB, et al. Longitudinal analysis of fibroblast growth factor expression after transplantation and association with severity of cardiac allograft vasculopathy. Circulation 1999; 100: 2396.
46. Farrell DJ, Hines JE, Walls AF, et al. Intrahepatic mast cells in chronic liver diseases. Hepatology 1995; 22: 1175.
47. Nakamura A, Yamazaki K, Suzuki K, et al. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am J Gastroenterol 1997; 92: 2245.
48. Buvry A, Garbarg M, Dimitriadou V, et al. Phenotypic and quantitative changes in mast cells after syngeneic unilateral lung transplantation in the rat. Clin Sci (Lond) 1996; 91: 319.
49. Zweifel M, Hirsiger H, Matozan K, et al. Mast cells in ongoing acute rejection: Increase in number and expression of a different phenotype in rat heart transplants. Transplantation 2002; 73: 1707.
50. Yamada M, Ueda M, Naruko T, et al. Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int 2001; 59: 1374.
51. Ishida T, Hyodo Y, Ishimura T, et al. Mast cell numbers and protease expression patterns in biopsy specimens following renal transplantation from living-related donors predict long-term graft function. Clin Transplant 2005; 19: 817.
52. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2: 46.
53. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693.
54. Fu S, Zhang N, Yopp AC, et al. TGF-beta induces Foxp3-T-regulatory cells from CD4- CD25- precursors. Am J Transplant 2004; 4: 1614.
55. Chen ZM, O'Shaughnessy MJ, Gramaglia I, et al. IL-10 and TGF-beta induce alloreactive CD4- CD25- T cells to acquire regulatory cell function. Blood 2003; 101: 5076.
56. Thornton AM, Piccirillo CA, Shevach EM. Activation requirements for the induction of CD4- CD25- T cell suppressor function. Eur J Immunol 2004; 34: 366.
57. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995.
58. Groux H, O'Garra A, Bigler M, et al. A CD4- T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737.
59. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789.
60. Levings MK, Bacchetta R, Schulz U, et al. The role of IL-10 and TGFbeta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129: 263.
61. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99.
62. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001; 103: 131.
63. Steinbrink K, Graulich E, Kubsch S, et al. CD4(-) and CD8(-) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99: 2468.
64. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762.
65. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191.
66. Kushnir-Sukhov NM, Brown JM, Wu Y, et al. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol 2007; 119: 498.
67. Gazi IF, Liberopoulos EN, Athyros VG, et al. Statins and solid organ transplantation. Curr Pharm Des 2006; 12: 4771.
68. Mach F. Statins as immunomodulatory agents. Circulation 2004; 109: II15.
69. Krauth MT, Majlesi Y, Sonneck K, et al. Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy 2006; 61: 281.